(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Adverum Biotechnologies's earnings in 2025 is -$204,392,000.On average, 8 Wall Street analysts forecast ADVM's earnings for 2025 to be -$146,936,582, with the lowest ADVM earnings forecast at -$189,314,280, and the highest ADVM earnings forecast at -$82,061,945. On average, 8 Wall Street analysts forecast ADVM's earnings for 2026 to be -$80,955,864, with the lowest ADVM earnings forecast at -$178,496,321, and the highest ADVM earnings forecast at -$12,286,110.
In 2027, ADVM is forecast to generate -$68,852,996 in earnings, with the lowest earnings forecast at -$151,451,424 and the highest earnings forecast at -$3,477,201.